TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations Meeting Abstract
| Authors: | Loriot, Y.; Zhang, A.; Hansen, A.; Mantia, C.; Boni, V.; Weickhardt, A.; Yu, E. Y.; Robert, M.; Iyer, G.; Murtha, A.; Owens, S.; Suttle, B.; Vandekerkhove, G.; Wyatt, A.; Gammon, G.; Burn, T.; Tran, B. |
| Abstract Title: | TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations |
| Meeting Title: | 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 211 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Oct 23-25 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-10-01 |
| Start Page: | S32 |
| End Page: | S33 |
| Language: | English |
| ACCESSION: | WOS:001345547300071 |
| DOI: | 10.1016/j.ejca.2024.114599 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 72 (PB060) -- Article number: 114599 -- Source: Wos |
